Nyxoah (NASDAQ:NYXH) Given New $3.00 Price Target at Cantor Fitzgerald

Nyxoah (NASDAQ:NYXH) had its price target lowered by Cantor Fitzgerald to $3.00 in a report issued on Tuesday, MarketBeat.com reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective suggests a potential upside of 229.38% from the company’s previous close.

A number of other analysts have also issued reports on NYXH. Oppenheimer set a $4.00 target price on shares of Nyxoah in a research report on Thursday, August 6th. Wall Street Zen lowered shares of Nyxoah from a “hold” rating to a “sell” rating in a research report on Sunday, August 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Nyxoah in a research report on Wednesday, August 19th. Robert W. Baird set a $2.31 target price on shares of Nyxoah in a research report on Thursday, August 6th. Finally, Piper Sandler restated an “overweight” rating and set a $6.00 target price (down from $7.00) on shares of Nyxoah in a research report on Thursday, August 6th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.55.

Nyxoah Trading Up 6.4%

NASDAQ NYXH traded up $0.05 during mid-day trading on Tuesday, reaching $0.91. 295,870 shares of the stock were exchanged, compared to its average volume of 206,015. Nyxoah has a 1-year low of $0.80 and a 1-year high of $5.92. The business’s fifty day simple moving average is $1.40 and its 200 day simple moving average is $2.60. The stock has a market capitalization of $35.30 million, a PE ratio of -0.36 and a beta of 1.65. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.31 and a current ratio of 2.38.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20). Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. The firm had revenue of $8.76 million for the quarter, compared to analyst estimates of $8.64 million. On average, research analysts anticipate that Nyxoah will post -1.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nyxoah

A number of large investors have recently bought and sold shares of NYXH. Integrated Wealth Concepts LLC purchased a new position in Nyxoah during the second quarter worth approximately $169,000. IFP Advisors Inc raised its stake in Nyxoah by 35.6% during the second quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock worth $200,000 after purchasing an additional 31,061 shares during the period. Finally, Readystate Asset Management LP purchased a new position in Nyxoah during the second quarter worth approximately $351,000.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.